The $125M Bet on Making Blind Eyes See Again

It's like losing your starting quarterback and teaching your tight end to throw. Unconventional? Sure. But if it works, you don't need to care which genetic mutation caused the original problem. One therapy could potentially treat all forms of RP.

The FDA Is Paying Attention

On April 1, 2026, the FDA granted RTx-015 its Regenerative Medicine Advanced Therapy (RMAT) designation. This isn't just a pat on the back. RMAT gives a company intensive FDA guidance, potential rolling review of its application, and a possible path to accelerated approval using surrogate endpoints (essentially, proving the drug works using indirect measures rather than waiting years for long-term data).

The FDA has been selective with these designations. As of September 2025, the agency had received 358 RMAT requests and granted about 152 of them. Of those designations, just 13 products had made it all the way to marketing approval. Getting the designation is meaningful; it means the FDA looked at early data and decided this therapy has real potential to address a serious unmet need.

RTx-015 is currently in its Phase 1 ENVISION study, an open-label trial testing four dose levels via single intravitreal injection (a shot into the eye, which sounds worse than it is) in about 18 adults with RP or choroideremia. Detailed results haven't been disclosed yet, but the RMAT designation suggests the preliminary data was encouraging enough to catch the FDA's eye.

A Crowded Race With Plenty of Room

Ray isn't the only company chasing vision restoration. The competitive landscape is heating up fast.

Beacon Therapeutics completed enrollment in its pivotal VISTA trial in July 2025, with 12-month data expected in the second half of 2026. Ocugen has 140 participants fully enrolled in a Phase 3 trial for its own gene-agnostic approach, with results expected in early 2027. And MeiraGTx recently acquired a gene therapy for X-linked RP from Johnson & Johnson, though J&J's Phase 3 trial showed mixed results (improvements on secondary measures, but a miss on the primary endpoint).

The only FDA-approved gene therapy for any retinal dystrophy remains Luxturna, which Spark Therapeutics launched back in 2017. But Luxturna only treats patients with a specific RPE65 mutation, covering a tiny slice of the broader RP population. For the vast majority of RP patients, there's still nothing.

That enormous gap is precisely what makes Ray's mutation-agnostic approach so compelling to investors. If RTx-015 works regardless of genetic cause, it could address a market that gene-specific therapies simply can't reach.

Where the Money Goes Next

The $125 million will fund two priorities. First, pushing RTx-015 through late-stage clinical development and preparing for commercialization. Second, advancing RTx-021, a pipeline candidate targeting Stargardt disease and geographic atrophy (a form of advanced macular degeneration).

Both therapies are built on the same optogenetics platform, delivered as single intravitreal injections. If the platform proves itself with RTx-015, the second program gets a major credibility boost for free.

The Personal Angle

There's a detail about Ray Therapeutics that makes this story hit differently. CEO and co-founder Paul Bresge started this company because his daughter was diagnosed with retinitis pigmentosa. His co-founder, Sean Ainsworth, previously ran RetroSense, one of the early pioneers in optogenetic therapy. These aren't executives chasing a market opportunity on a spreadsheet. They've been in the vision restoration space for years, driven by something more personal than IRR calculations.

That doesn't guarantee success, of course. Biotech is littered with promising therapies that looked great in early trials and fell apart later. The ENVISION study is still small, the data is still preliminary, and the jump from Phase 1 to approval is long and treacherous.

But $125 million in oversubscribed funding, an RMAT designation, and a mechanism that sidesteps RP's genetic complexity? That's a hand worth playing. For the millions of people watching their world go dark, it might be the most important bet in ophthalmology right now.

The Sage Vets Who Raised $106M to Take Another Swing at the Brain

Two former Sage Therapeutics leaders just launched a brain-focused biotech with $106 million and four clinical-stage drugs. In a therapeutic area where 85% of drugs fail, they're betting their track record (and two FDA approvals) can beat the odds.